Diversify Wealth Management LLC Increases Stake in IDEXX Laboratories, Inc. $IDXX

Diversify Wealth Management LLC raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 87.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,097 shares of the company’s stock after acquiring an additional 979 shares during the period. Diversify Wealth Management LLC’s holdings in IDEXX Laboratories were worth $1,161,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in IDXX. Valmark Advisers Inc. lifted its position in IDEXX Laboratories by 13.5% in the first quarter. Valmark Advisers Inc. now owns 2,188 shares of the company’s stock valued at $1,229,000 after purchasing an additional 260 shares during the period. Carnegie Investment Counsel increased its position in IDEXX Laboratories by 1.3% during the 1st quarter. Carnegie Investment Counsel now owns 2,000 shares of the company’s stock worth $1,124,000 after purchasing an additional 25 shares during the period. UNIVEST FINANCIAL Corp increased its position in IDEXX Laboratories by 1.9% during the 1st quarter. UNIVEST FINANCIAL Corp now owns 6,590 shares of the company’s stock worth $3,703,000 after purchasing an additional 126 shares during the period. Midwest Trust Co raised its stake in shares of IDEXX Laboratories by 1.5% during the 1st quarter. Midwest Trust Co now owns 18,024 shares of the company’s stock worth $10,128,000 after buying an additional 274 shares in the last quarter. Finally, Fifth Third Bancorp raised its stake in shares of IDEXX Laboratories by 217.3% during the 1st quarter. Fifth Third Bancorp now owns 23,848 shares of the company’s stock worth $13,400,000 after buying an additional 16,332 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 3.0%

IDXX opened at $557.02 on Thursday. The business’s fifty day moving average is $554.27 and its two-hundred day moving average is $600.97. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The company has a market cap of $43.94 billion, a price-to-earnings ratio of 41.02, a PEG ratio of 2.96 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the business posted $2.91 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday. Finally, UBS Group decreased their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.